Abstract
Hepatitis B virus (HBV) infection is a global public health problem and it is also a major health concern of Turkey. The estimated number of HBV carriers in Turkey is about 3.3 million, with an overall HBV prevalence of 4.57%. Thus, both prevention and therapy of HBV-infected patients are urgent medical need of Turkey. A total of 1,533 among 37,637 patients who were examined at the Department of Gastroenterology, Ankara University School of Medicine were found to be hepatitis B surface antigen (HBsAg) positive (4%). Viral hepatitis treatment is fully reimbursed in Turkey through the national insurance system, which covers all residents across Turkey.How to cite this article: Özkan H. Epidemiology of Chronic Hepatitis B in Turkey. Euroasian J Hepato-Gastroenterol 2018;8(1):73-74.
Highlights
Hepatitis B is one of the most common infectious diseases worldwide
The overall prevalence of the hepatitis B surface antigen (HBsAg) has been previously reported to be in the range of 4.0 to 5.0%, which has decreased to 2.0% in recent years
The Turkish Society of Viral Hepatitis researched the prevalence of Hepatitis B virus (HBV) among 73,175 people
Summary
Hepatitis B is one of the most common infectious diseases worldwide. Estimates indicate that almost 2 billion people have been infected with HBV, with more than 380 million people being chronic carriers (6% of the world population on average).Among all chronic hepatitis B (CHB) cases, approximately 40% will develop cirrhosis, liver failure, or hepatocellular carcinoma. Epidemiology of Chronic Hepatitis B in Turkey. Estimates indicate that almost 2 billion people have been infected with HBV, with more than 380 million people being chronic carriers (6% of the world population on average). Among all chronic hepatitis B (CHB) cases, approximately 40% will develop cirrhosis, liver failure, or hepatocellular carcinoma.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have